| Literature DB >> 35290890 |
Tengfei Li1, Shuai Zhou2, Yan Yang3, Yanyan Xu3, Xin Gong3, Yunsheng Cheng3, Yong Wang4.
Abstract
To date, recent studies have shown that long non-coding RNAs (lncRNAs) are key players in gene regulation processes involved in cancer pathogenesis. In general, Motor neuron and pancreas homeobox 1-antisense RNA1 (MNX1-AS1) is highly expressed in all cancers as reported so far and exerts oncogenic effects through different mechanisms. In this review, we comprehensively summarize the detailed mechanisms of potential functions of MNX1-AS1 in different cancer types as well as the latest knowledge highlighting the potential of MNX1-AS1 as a therapeutic target for cancer. Aberrant expression of MNX1-AS1 closely correlates with clinicopathological parameters. such as lymphatic metastasis, tumor size, tumor stage, OS and DFS. Thus, MNX1-AS1 can be used as a diagnostic and prognostic biomarker or even a therapeutic prognostic target. This article reviews its function, molecular mechanism and clinical prognosis in various malignancies.Entities:
Keywords: Biomarker; Cancer; Long noncoding RNA; MNX1-AS1; Oncogenic
Mesh:
Substances:
Year: 2022 PMID: 35290890 DOI: 10.1016/j.biopha.2022.112801
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529